GEN ILAC VE SAGLIK URUNLERI SANAYI VE TICARET ANONIM SIRKETI Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Share Price
Equities
GENIL
TREGENL00024
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.05 TRY | -1.21% |
|
-3.71% | +21.69% |
| Sales 2022 | 5.45B 168M 13.42B | Sales 2023 | 8.15B 252M 20.09B | Capitalization | 14.06B 434M 34.65B |
|---|---|---|---|---|---|
| Net income 2022 | 1.08B 33.35M 2.66B | Net income 2023 | 455M 14.05M 1.12B | EV / Sales 2022 | 2.76 x |
| Net cash position 2022 | 494M 15.26M 1.22B | Net Debt 2023 | 594M 18.34M 1.46B | EV / Sales 2023 | 1.8 x |
| P/E ratio 2022 |
14.4
x | P/E ratio 2023 |
30.9
x | Employees | 622 |
| Yield 2022 |
2.15% | Yield 2023 |
-
| Free-Float | 25.75% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.21% | ||
| 1 week | -3.71% | ||
| Current month | -14.72% | ||
| 1 month | -14.72% | ||
| 3 months | +8.36% | ||
| 6 months | -6.40% | ||
| Current year | +21.69% |
1 week
56.90
59.35
1 month
54.2075.90
Current year
44.7884.50
1 year
35.9484.50
3 years
11.8284.50
5 years
11.8284.50
10 years
11.8284.50
| Managers | Title | Age | Since |
|---|---|---|---|
Nadir Ulu
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/23 |
Ali Ketencioglu
IRC | Investor Relations Contact | - | 31/08/21 |
| Sales & Marketing | - | 31/07/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Abidin Gulmus
CHM | Chairman | - | - |
Sukru Turkmen
BRD | Director/Board Member | - | - |
Ömer Dinçer
BRD | Director/Board Member | - | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 57.05 | -1.21% | 568 925 |
| 26/04/24 | 57.75 | +0.43% | 966,063 |
| 25/04/24 | 57.5 | +0.26% | 787,715 |
| 24/04/24 | 57.35 | -3.21% | 1,538,479 |
| 22/04/24 | 59.25 | +1.11% | 1,632,512 |
Delayed Quote Borsa Istanbul, April 29, 2024 at 11:41 am
More quotes
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is a Turkey-based company, which engages in manufacturing of pharmaceuticals and other health products. The Company operates in the fields of manufacturing all kinds of pharmaceuticals for human use and health products, trading, import and export. Gen Ilac manufactures products used in the treatment of rare diseases and disorders in neurology, endocrinology, nephrology, oncology, hematology and pediatric branches. The Company has approximately 500 employees working in its production facilities on a closed area of 15,000 square meters, established on an area of approximately 43,000 square meters in Ankara ASO 2nd and 3rd Organized Industrial Zone. Entity has 5 offices abroad: Germany, Russia, Kazakhstan, Uzbekistan and Azerbaijan.
Sector
Pharmaceuticals
Calendar
05/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +21.69% | 534M | |
| +25.83% | 661B | |
| +26.83% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.89% | 231B | |
| +5.28% | 200B | |
| -8.83% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- GENIL Stock
